Value in Multiple Sclerosis Management and Specialty Pharmaceuticals
Pharmacoeconomics has been used, in various ways, at the institutional level, for formulary decision making around specialty pharmaceuticals. This program reviews the role of pharmacoeconomics and cost-effectiveness thresholds, along with mechanisms that influence and affect drug policy listing decisions.
This program has received an unrestricted educational grant or in-kind support from Pharmascience.
This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for 1.0 CEUs.
Ahmad Alghamdi, Pharm D., Ph.D, HEOR
Consultant, Assistant Professor of Pharmaceutical Economics & Policy
President of the Saudi Pharmacoeconomics Experts Group
A researcher and assistant professor with a demonstrated history of working in the higher education industry. Dr. Alghamdi is a PhD holder in Pharmaceutical Economics and Policy.
Hana Al-Abdulkarim, BSc, MSc, HEOR, MSc
Director, Drug Policy and Economic Center, Ministry of National Guard Health Affairs, Riyadh, KSAH.
Moe Abdallah, B.SC., B.SC.PHM., R.PH
Clinical pharmacist, Drug Programs Policy and Strategy Branch
Ontario Public Drug Programs
Ministry of Health and Long-Term Care
Michael Boivin, RPh, BScPhm
Clinical Pharmacist Consultant and Continuing Education Developer
After viewing this expert brief, participants will be better able to:
- Explain the key principles of value and value-based healthcare.
- Apply the principles of value-based healthcare to multiple sclerosis (MS) management.
- Describe the elements of determining value for specialty pharmaceuticals.
- Discuss the benefits provided by patient support programs (PSPs) and their relevance in the assessment of value of specialty pharmaceuticals.